No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina / NY / Florida       

American Lung Association Increases Research Investment; Funds $12.6 Million in Lung Health Grants

Organization funds more than 100 promising research grants, including on COVID-19, lung cancer and vaping policy

Editor: What To Know

  • Research projects funded by the Lung Association are carefully selected through a rigorous review committee and represent the investigation of a wide range of complex issues to help reduce the burden of lung disease.
  • The funded projects address a wide range of lung health topics, including COVID-19 in children, the public health impacts of e-cigarette policy and lung cancer in never smokers.
  • Reddy’s research will use a new simulation model of tobacco and nicotine use to project the impact of various e-cigarette policies on e-cigarette use, tobacco smoking, and downstream health effects among U.

At a time when lung health is more important than ever, the American Lung Association announced today that it has increased its research funding to award $12.6 million for more than 100 research grants.

The funded projects address a wide range of lung health topics, including COVID-19 in children, the public health impacts of e-cigarette policy and lung cancer in never smokers.

“Each day, we face new and pressing lung health challenges from the ongoing COVID-19 pandemic to climate change and youth e-cigarette use. For more than 115 years, the American Lung Association has been the trusted champion of lung health by helping people manage lung disease, educating healthcare providers to better treat their patients and now investing even more in lung health research,” said American Lung Association President and CEO Harold Wimmer. “With these new research projects, we empower some of the best scientists to fundamentally change how lung diseases, including lung cancer, impact our lives.”

Research projects funded by the Lung Association are carefully selected through a rigorous review committee and represent the investigation of a wide range of complex issues to help reduce the burden of lung disease. Awards are given in eight different categories; ALA/AAAAI Allergic Respiratory Diseases Award, ALA/ATS/CHEST Foundation Respiratory Health Equity Research Award, Catalyst Award, COVID-19 Respiratory Virus Research Award, Dalsemer Award, Innovation Award, Lung Cancer Discovery Award, and Public Policy Research Award.

In total, $12.6 million was awarded to more than 100 grants, including seven new COVID-19 research grants. Meet our full research team, including our current awardees, and read the full abstracts at Lung.org/research-team. A few of the recent grant awardees include:

  • Lung Cancer Discovery Award presented to Lixing Yang, Ph.D., from the University of Chicago for his project titled “Discovery of New Oncogenes in Lung Cancers in Never Smokers.” Yang aims to discover which genetic changes might cause lung cancer using information from 2,500 tumors of never smokers collected by the National Cancer Institute. While tobacco smoking is the main cause of lung cancer, as many as 25% of lung cancers occur in never smokers, but very few studies have been done on these tumors. Through this research, Yang expects to find novel drug targets and improve patient care and survival.
  • Innovation Award presented to Krishna Reddy, Ph.D., from Massachusetts General Hospital for the project “The Public Health Impact of Electronic Cigarette Policies.” Reddy’s research will use a new simulation model of tobacco and nicotine use to project the impact of various e-cigarette policies on e-cigarette use, tobacco smoking, and downstream health effects among U.S. youth and adults. The findings will provide clinicians and public health officials with data to more quickly inform policy decisions around e-cigarettes.
  • COVID-19 Respiratory Virus Research Award presented to Bria Coates, M.D., from Ann & Robert H. Lurie Children’s Hospital of Chicago for her project titled “Cross-reactive T Cells and Severity of Illness in SARS-CoV-2 Infection in Children and Adults.” This research project will study how age affects the immune system response in fighting the SARS-CoV-2 virus. These findings will help clinicians understand how the virus affects children and adults and better personalize treatment.

Just last month, the Lung Association announced COVID-19 research grants through its COVID-19 Action Initiative, a $25 million investment in research, education, advocacy and coalition over the next three years. The COVID-19 Action Initiative provides free lung health education to those in need, protects public health by advocating for COVID-19 and flu vaccines in underserved communities, and prevents future outbreaks by investing in respiratory virus research.

For more information about the new grant awardees and the entire American Lung Association Research Team, visit Lung.org/research-team.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy